[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561818":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":31,"responsibleParty":47,"collaborators":20,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":20,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Yonsei University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with advanced hepatocellular carcinoma","EXPERIMENTAL","Patients indicated for the first-line atezolizumab-bevacizumab combination therapy are the primary subjects, and those voluntarily agree to the clinical trial after explanation of the study, are enrolled in the study.",[13],"Radiation: Stereotactic body radiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Stereotactic body radiotherapy","Patients with advanced hepatocellular carcinoma who are indicated for the first-line atezolizumab-bevacizumab combination therapy are the primary subjects, and they should begin stereotactic radiotherapy to one or more but not more than five sites for primary cancer and\u002For metastatic lesions within two month before and after the start date of atezolizumab-bevacizumab combination therapy.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Hwakyung BYUN, Phd","Severance Hospital","PRINCIPAL_INVESTIGATOR",[27],{"name":23,"role":28,"phone":29,"phoneExt":20,"email":30},"CONTACT","007981072098955","hkbyun05@yuhs.ac",[32],{"facility":33,"status":34,"city":35,"state":20,"zip":36,"country":37,"countryCode":20,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Yongin Severance Hospital","RECRUITING","Yongin-si","365","South Korea",{"type":39,"coordinates":40},"Point",[41,42],127.08042,37.29686,{"lat":42,"lon":41},[45],{"name":23,"role":28,"phone":46,"phoneExt":20,"email":30},"0079803151898166",{"type":25,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Hwa Kyung Byun","Professor","100561818","atezolizumab-and-bevacizumab-with-stereotactic-body-radiotherapy-for-advanced-hepatocellular-carcinoma-100561818",false,"NCT06595108","Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma","Atezolizumab and Bevacizumab With Stereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma","A-BEST","Inclusion Criteria:\n\n1. Age 19 to 80 years old\n2. Liver function Child-Pugh class A\n3. ECOG 0-1\n4. Patient clinically or pathologically diagnosed with hepatocellular carcinoma\n5. Advanced hepatocellular carcinoma that is inoperable\n6. Satisfies the dose limits for normal organs and lesions of an appropriate size to be included in the scope of radiotherapy.\n\nExclusion Criteria:\n\n1. Brain metastases\n2. Have a history of malignancy other than hepatocellular carcinoma within the last 5 years (except for malignancies with little risk of metastasis or death, e.g., adequately treated cervical carcinoma in situ, non-melanoma skin cancer, localized prostate cancer, tubular carcinoma in situ, or stage 1 uterine cancer.)\n3. Subjects with a high probability of untreated gastric or esophageal varices or bleeding\n4. Serious uncontrolled medical comorbidities\n5. History of liver transplant surgery\n6. Autoimmune liver disease","ALL","19 Years","80 Years",{"count":62,"type":63},33,"ESTIMATED","INTERVENTIONAL",[66],"NA","To determine the efficacy and safety of atezolizumab-bevacizumab combination therapy plus stereotactic body radiotherapy(SBRT) in patients with advanced hepatocellular carcinoma, Subjects will start SBRT for one or more primary cancers and\u002For metastatic lesions and no more than 5 sites within two month before and after the start date of atezolizumab-bevacizumab combination therapy.\n\nIn this study, it is expected to improve the treatment response rate of atezolizumab-bevacizumab therapy, which is currently first-line chemotherapy but has a low treatment response rate.",[69,70,71],"Advanced Hepatocellular Carcinoma","Chemotherapy","Stereotactic Body Radiotherapy",[73,74],"atezolizumab-bevacizumab","SBRT","2024-10-30",{"date":77,"type":78},"2024-11-01","ACTUAL",{"date":80,"type":78},"2024-05-28",{"date":82,"type":63},"2028-03-27",{"name":5,"class":6},1]